Press Releases

Stay informed about the newest developments at Genescopy and explore how we are revolutionizing gastrointestinal health.

Find out more

Geneoscopy Advances Mission to Transform Gastrointestinal Health at Digestive Disease Week 2024

Company highlights capabilities of noninvasive stool-based RNA technology platform for improving patient outcomes in IBD and CRC ST, LOUIS, MO – MAY 24, 2024 –…


Court Dismisses Exact Sciences’ ‘781 Patent Infringement Claim Against Geneoscopy

Geneoscopy Continues Path Toward Commercialization of ColoSense, Bringing New Innovations in Gastrointestinal Health to Patients in Need ST, LOUIS, MO – MAY…


Geneoscopy Expands Leadership Team to Support ColoSense™ Rollout and Advance Precision IBD Solution

ST, LOUIS, MO – MAY 15, 2024 – Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal…


FDA Approves ColoSense™ – Geneoscopy’s Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

In average-risk individuals, ColoSense demonstrated 93% sensitivity for detecting colorectal cancer (CRC) and 45% sensitivity for detecting advanced adenomas…


Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference

Data shows noninvasive stool RNA technology may help providers assess therapeutic response and monitor disease activity for patients with inflammatory bowel…


Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)

ST. LOUIS, MO – January 17, 2024 – Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal…


Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent

Extensive prior art renders Exact Sciences’ patent relating to stool collection and processing invalid ST. LOUIS, Mo. – (BUSINESS WIRE) – January…


Geneoscopy and Adiso Therapeutics Announce Strategic Collaboration to Investigate New Therapeutic Options for Patients with Inflammatory Bowel Disease

                                                        Adiso to Utilize Noninvasive RNA Technology Developed by Geneoscopy as a Precision Immunology Measure…


Geneoscopy Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

Collaboration expected to increase provider and patient access to potentially life-saving colorectal cancer screening that enables earlier disease detection…


Don Hardison Appointed Chairman of the Board at Geneoscopy

ST. LOUIS. MO – November 9, 2023 – Geneoscopy, a life sciences company focused on developing diagnostic tests for gastrointestinal health, has appointed Don…


JAMA Publishes Geneoscopy’s Pivotal CRC-PREVENT Trial Results, Reporting Highest Sensitivity for Detecting Colorectal Cancer and Advanced Adenomas Among Available Noninvasive Screening Tests

Geneoscopy’s noninvasive, multi-target, stool RNA (mt-sRNA) colorectal cancer screening test showed extraordinary sensitivity for detecting early-stage…


Geneoscopy to Present and Exhibit at American College of Gastroenterology 2023 Annual Meeting

Company to Showcase Its Noninvasive RNA-based Technology Platform Designed to Improve Diagnostic Tools for Gastrointestinal Health ST LOUIS, MO – Oct. 5,…


Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

“…We believe that our pipeline of tests will enable a precision medicine approach to GI disease management and treatment, bringing value to…


Geneoscopy Joins White House for Cancer Moonshot Colorectal Cancer Forum

“As leaders, we have a responsibility to come together to impact cancer. Colorectal cancer is one of the most preventable and treatable cancers when…


Geneoscopy appoints Don Hardison to its Board of Directors

ST. LOUIS, Feb. 28, 2023 /PRNewswire/ Geneoscopy, a developer of innovative diagnostics for gastrointestinal health, announced the appointment of Don Hardison…


Geneoscopy Submits Premarket Approval Application to FDA for its Noninvasive Colorectal Cancer RNA Biomarker Screening Test

FDA’s Decision Forthcoming for Innovative Test with Agency’s Breakthrough Device Designation ST LOUIS, Jan. 24, 2023 / — Geneoscopy, Inc., a life…


Geneoscopy’s Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial

Colorectal Cancer and Advanced Adenoma Sensitivity Results are the Highest Reported from any Prospective Pivotal Study for a Noninvasive Screening Test…


Geneoscopy announces rebranding

New look matches focus on transforming GI health ST. LOUIS, MISSOURI (October 3, 2022)  |  Geneoscopy today announced a corporate rebrand and…


Geneoscopy Completes Pivotal Colorectal Cancer Trial Enrollment with Diverse Participant Population

Trial Enrollment Over Indexes in Traditionally Under-Represented Black Community ST. LOUIS, Aug. 23, 2022 /PRNewswire/ -- Geneoscopy Inc., a life sciences…


Geneoscopy to Join Fight CRC at the White House to Address Colorectal Cancer Screening Needs

ST. LOUIS, MISSOURI (JULY 19, 2022) | Earlier this year, President Joe Biden announced plans to reignite the Cancer Moonshot with renewed leadership and…


Geneoscopy Announces Formation of Scientific Advisory Board to Inform Strategy for the Advancement of Gastrointestinal Health

ST. LOUIS, June 21, 2022 /PRNewswire/ -- Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI)…


Geneoscopy Cost-Effectiveness Modeling Data Demonstrates Potential to Reduce Colorectal Cancer Cases and Deaths in the United States with RNA-FIT Screening Test

Data at 2022 Digestive Disease Week Meeting Also Shows RNA-FIT Test to Be Cost-Effective ST. LOUIS, May 23, 2022 /PRNewswire/ -- Geneoscopy Inc., a life…


Geneoscopy Tackles Healthcare Disparities in Pivotal Colorectal Cancer Clinical Trial Utilizing a Digital Recruitment Strategy

Trial Enrollment Data Presented at 2022 ASCO Gastrointestinal Cancers Symposium ST. LOUIS, Jan. 20, 2022 /PRNewswire/ -- Geneoscopy Inc., a life sciences…


Geneoscopy Announces Positive Results of Colorectal Cancer Screening Test in Prospective, Multicenter Clinical Study

Study Results Show Diagnostic Accurately Detects Colorectal Cancer and Precancerous Adenomas With High Sensitivity ST. LOUIS--(BUSINESS WIRE)--Geneoscopy…


Geneoscopy Closes $105M in Financing to Advance its Noninvasive Multifactor RNA Screening Test for Colorectal Cancer Prevention

Funding to support U.S. CRC-PREVENT pivotal trial, scale commercial infrastructure, and expand diagnostic product pipeline ST. LOUIS, Nov. 16,…


Geneoscopy Appoints Dr. Haytham Gareer as Chief Medical Officer

Seasoned medical affairs executive to advance company's diagnostics product pipeline ST. LOUIS, Mo., Oct. 18, 2021  /PRNewswire/ -- Geneoscopy Inc., a life…


Geneoscopy Honored by Goldman Sachs for Entrepreneurship

Andrew Barnell, CEO, Among 100 Most Intriguing Entrepreneurs at 2021 Builders + Innovators Summit ST. LOUIS, Oct. 13, 2021 /PRNewswire/ – Geneoscopy Inc., a…


Geneoscopy Enrolls First Patients in CRC-PREVENT U.S. Pivotal Trial

Clinical Trial Investigates Company's Noninvasive Multifactor RNA Screening Test for Colorectal Cancer Prevention ST. LOUIS, July 12, 2021 /PRNewswire/ --…


Geneoscopy Announces Publication of Peer-Reviewed Article Highlighting Effective Noninvasive Screening Test for Colorectal Cancer Prevention

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy Inc. today announced publication of the peer-reviewed article, “Multitarget Stool RNA Test for Noninvasive Detection of…


Geneoscopy Appoints Don Hardison to its Strategic Advisory Board

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced the…


Geneoscopy Appoints Vince Wong as Chief Commercial Officer

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced the…


Geneoscopy’s Preventive Screening Test for Colorectal Cancer and Precancerous Adenomas Earns FDA Breakthrough Device Designation

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today…


Geneoscopy Raises $6.9 Million to Advance Preventive Screening Test for Colorectal Cancer and Advanced Adenomas

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today…